Jacob Johnson
Stock Analyst at Stephens & Co.
(4.02)
# 607
Out of 4,734 analysts
83
Total ratings
47.69%
Success rate
13.67%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MASS 908 Devices | Reiterates: Overweight | $6 | $2.98 | +101.34% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $6.48 | -7.41% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $52.63 | +14.00% | 6 | Jan 2, 2025 | |
| STE STERIS | Reiterates: Overweight | $260 | $209.62 | +24.03% | 6 | Nov 7, 2024 | |
| DHR Danaher | Reiterates: Overweight | $315 | $238.36 | +32.15% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher | Initiates: Overweight | $680 | $559.65 | +21.50% | 1 | Oct 1, 2024 | |
| CDMO Avid Bioservices | Reiterates: Overweight | $12 | $12.39 | -3.15% | 7 | Sep 10, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $160.51 | +5.91% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $8.07 | -38.04% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $4.94 | +122.67% | 5 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 | $22.85 | +66.30% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $7.50 | +126.67% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.79 | +39.66% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $75.83 | +14.73% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $336.34 | +15.95% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $14.21 | +26.67% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $5.00 | +20.00% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $26.14 | +10.94% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $111.89 | +16.19% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $163.50 | +130.58% | 1 | Apr 7, 2022 |
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.98
Upside: +101.34%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $6.48
Upside: -7.41%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $52.63
Upside: +14.00%
STERIS
Nov 7, 2024
Reiterates: Overweight
Price Target: $260
Current: $209.62
Upside: +24.03%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $238.36
Upside: +32.15%
Thermo Fisher
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $559.65
Upside: +21.50%
Avid Bioservices
Sep 10, 2024
Reiterates: Overweight
Price Target: $12
Current: $12.39
Upside: -3.15%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $160.51
Upside: +5.91%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $8.07
Upside: -38.04%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $4.94
Upside: +122.67%
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $22.85
Upside: +66.30%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $7.50
Upside: +126.67%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.79
Upside: +39.66%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $75.83
Upside: +14.73%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $336.34
Upside: +15.95%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $14.21
Upside: +26.67%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $5.00
Upside: +20.00%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $26.14
Upside: +10.94%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $111.89
Upside: +16.19%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $163.50
Upside: +130.58%